Nf Κb (Nuclear Factor Kappa B) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
NF-κB[1] (nuclear factor kappa-light-chain-enhancer of activated B cells) is a family of transcription factors that plays central roles in [inflammation], immune responses, cell survival, and synaptic plasticity. In the central nervous system, NF-κB[1] is activated in neurons, astrocytes, and microglia/entities/microglia, where it serves as a critical mediator linking [neuroinflammation[3]] to [neuronal death] in Alzheimer's disease, Parkinson's disease, ALS, and Huntington's disease (Mattson & Camandola, 2001; Singh & Singh, 2020).
NF-κB[1] occupies a paradoxical position in
neurodegeneration: in neurons, it is generally neuroprotective, promoting survival through anti-apoptotic gene expression, while in
[microglia/cell-types/microglia and astrocytes it drives pro-inflammatory cascades that exacerbate neuronal damage
(Jha et al., 2024). This dual nature makes NF-κB[1] both a compelling and a challenging therapeutic target.
The NF-κB[1] family consists of five related proteins that form homo- and heterodimers with distinct DNA-binding specificities and transcriptional targets (Hayden & Ghosh, 2008):
| Subunit |
Gene |
Precursor |
Key Features |
| p65 (RelA) |
RELA |
— |
Contains transactivation domain; most abundant subunit in CNS |
| RelB |
RELB |
— |
Induces distinct transcriptional programs via non-canonical pathway |
| c-Rel |
REL |
— |
Important for lymphocyte function; expressed in neurons |
| p50 (NF-κB[1]1) |
NFKB1 |
p105 |
Processed from p105 precursor; lacks transactivation domain |
| p52 (NF-κB[1]2) |
NFKB2 |
p100 |
Processed from p100; active in non-canonical signaling |
The p65/p50 heterodimer is the most common transcriptionally active form in the brain and is the primary mediator of inflammatory gene expression in [microglia/cell-types/microglia and astrocytes (Karin & Ben-Neriah, 2000).
The canonical NF-κB[1] pathway is the primary signaling route in neuroinflammation[3] (Hayden & Ghosh, 2008):
- Stimulus recognition: Pro-inflammatory cytokines (TNF-α, IL-1β), pathogen-associated molecular patterns (via TLR4, or damage-associated molecular patterns (including amyloid-beta aggregates) activate upstream receptors.
- IKK complex activation: The IκB kinase (IKK) complex — consisting of IKKα, IKKβ, and the regulatory subunit NEMO (IKKγ) — is activated.
- IκB phosphorylation and degradation: IKKβ phosphorylates IκBα, marking it for K48-linked ubiquitination and [proteasomal degradation].
- Nuclear translocation: Freed NF-κB[1] dimers (typically p65/p50) translocate to the nucleus.
- Transcriptional activation: NF-κB[1] binds κB motifs in target gene promoters, inducing expression of cytokines, chemokines, [complement] components, and pro-survival genes.
This pathway mediates rapid, transient responses and is the primary driver of microglial inflammatory activation.
The non-canonical pathway involves NF-κB[1]-inducing kinase (NIK) and IKKα-mediated processing of p100 to p52, which pairs with RelB. This pathway produces slower, sustained responses and is particularly important for lymph node development and adaptive immune regulation. In the CNS, the non-canonical pathway contributes to astrocyte activation and synaptic maintenance (Sun, 2011).
¶ Neuronal NF-κB[1]: Neuroprotection and Synaptic Plasticity
In neurons, NF-κB[1] is constitutively active at low levels and serves primarily protective functions (Mattson, 2005):
Synaptic plasticity and memory:
- NF-κB[1] is rapidly activated in [hippocampal] neurons during long-term potentiation (LTP and is required for memory consolidation (Albensi & Mattson, 2000)
- Controls expression of synaptic scaffolding proteins (PSD-95, SAP97) and NMDA receptor] receptor] subunit NR2B
- Regulates BDNF transcription, linking activity to trophic support
- Required for late-phase LTP and long-term memory formation
Neuronal survival:
- Drives expression of anti-apoptotic genes (Bcl-2, Bcl-xL, IAPs, Mn-SOD)
- Protects against [excitotoxic] injury by buffering calcium responses
- Mediates neurotrophic factor signaling downstream of BDNF and GDNF
- Supports DNA repair mechanisms via Ku70/Ku80 expression
In contrast to its protective neuronal role, glial NF-κB[1] activation is a central driver of neurotoxic [neuroinflammation[3]]:
Microglial activation (Snow & Albensi, 2021):
- Canonical NF-κB[1] activation in [microglia/cell-types/microglia drives transcription of TNF-α, IL-1β, IL-6, and iNOS
- Cooperates with NLRP3 inflammasome] activation to promote IL-1β and IL-18 release
- Promotes transition to [disease-associated microglia (DAM) phenotype
- Induces expression of BACE1/entities/bace1, promoting amyloidogenic APP processing]
Astrocyte activation (Lian et al., 2024):
- Astrocytic NF-κB[1] promotes reactive astrogliosis and loss of neurotrophic support
- Drives production of [complement] component C3, which mediates [synapse elimination]
- Reduces glutamate transporter expression, contributing to excitotoxicity
- NF-κB[1]-dependent astrocytic activation leads to Aβ42 accumulation and iNOS generation
NF-κB[1] is chronically hyperactivated in Alzheimer's disease brain tissue, particularly in vulnerable regions including the hippocampus and [entorhinal cortex (Singh et al., 2022):
- neurons: Increased nuclear p65 in degenerating neurons adjacent to amyloid plaques
- microglia/entities/microglia: Sustained NF-κB[1] activation in plaque-associated [microglia
- astrocytes: Elevated NF-κB[1] activity in reactive astrocytes surrounding plaques
NF-κB[1] participates in a destructive feed-forward loop with amyloid-beta (Ju Hwang et al., 2022):
- Aβ oligomers] activate microglial TLR4 and RAGE receptors, triggering NF-κB[1]
- NF-κB[1] upregulates [BACE1 expression, increasing amyloidogenic processing of APP
- NF-κB[1]-driven pro-inflammatory cytokines further activate [BACE1 and [γ-secretase]
- More Aβ is produced, perpetuating the inflammatory cycle
- Aβ-induced ROS further amplify NF-κB[1] activation via redox-sensitive IKK
¶ NF-κB[1] and Tau Pathology
NF-κB[1] also links to tau] hyperphosphorylation]:
- NF-κB[1] activation upregulates the phosphatase inhibitor SET/I2PP2A, reducing PP2A activity
- Decreased PP2A activity leads to hyperphosphorylation of tau] at disease-relevant epitopes
- Glycated tau] triggers ROS production, further activating NF-κB[1]
- NF-κB[1]-dependent GSK-3β and CDK5 activation promotes tau] kinase activity
NF-κB[1] plays a significant role in dopaminergic neurodegeneration in Parkinson's disease (Singh & Singh, 2020):
- Immunohistochemical analyses of PD brain sections reveal a 70-fold increase in the proportion of dopaminergic neurons in the substantia nigra exhibiting nuclear p65 immunoreactivity compared to age-matched controls
- [alpha-synuclein/proteins/alpha oligomers potentiate neuroinflammatory NF-κB[1] signaling in [microglia/cell-types/microglia, amplifying dopaminergic neuron damage (Bido et al., 2024)
- NF-κB[1]-driven microglial activation is an early event in PD pathogenesis, preceding overt neuronal loss
- [LRRK2/proteins/lrrk2 mutations enhance NF-κB[1] signaling, linking genetic risk to inflammatory mechanisms
¶ Role in ALS and Huntington's Disease
ALS: Spinal cords of ALS patients show increased NF-κB[1] activation in astrocytes associated with degenerating motor neurons. Mutant [SOD1/proteins/sod1-mediated NF-κB[1] activation in glia contributes to non-cell-autonomous motor neuron toxicity (Mattson & Camandola, 2001).
Huntington's disease: In contrast to its deleterious role in AD and PD glia, neuronal NF-κB[1] appears protective in HD. Mice lacking the p50 subunit (NF-κB[1]1 knockout) exhibit increased [striatal] neuron damage and enhanced motor dysfunction after mitochondrial toxin exposure, indicating that NF-κB[1] activation serves a neuroprotective function in medium spiny neurons (Mattson & Camandola, 2001).
The opposing functions of NF-κB[1] in neurons (protective) versus glia (inflammatory) make therapeutic targeting extremely challenging (Jha et al., 2024):
- When neuronal NF-κB[1] is inhibited, pro-[apoptotic] signaling via caspase-8 predominates, accelerating neuronal death
- Global NF-κB[1] inhibition can impair immune defense and worsen outcomes
- Cell-type-specific targeting is needed but technically difficult
Direct NF-κB[1] inhibitors (Thakur et al., 2023):
- IKK inhibitors: BAY 11-7082, IMD-0354, BMS-345541 — block IκB phosphorylation
- Proteasome inhibitors: Bortezomib — prevents IκB degradation (limited CNS penetration)
- Decoy oligonucleotides: κB-motif decoys sequester NF-κB[1] dimers
Natural product modulators:
- Curcumin: Inhibits IKK activity and NF-κB[1] nuclear translocation; poor bioavailability limits clinical utility
- Resveratrol: Activates SIRT1, which deacetylates p65 and suppresses NF-κB[1] transcriptional activity
- Epigallocatechin gallate (EGCG): Suppresses NF-κB[1] through multiple mechanisms
Indirect approaches:
- NSAIDs: Indirectly inhibit NF-κB[1]; epidemiological data suggested reduced AD risk, but clinical trials have been mixed
- GLP-1 receptor agonists: Suppress microglial NF-κB[1] activation, showing neuroprotective effects in preclinical models
- Anti-TNF biologics: Block upstream NF-κB[1] activation; retrospective studies suggest reduced dementia risk
- Cell-type-specific delivery: Nanoparticles targeting [microglia/cell-types/microglia or astrocytes to spare neuronal NF-κB[1]
- Pathway-selective inhibition: Targeting the non-canonical pathway or specific NF-κB[1] dimers
- Epigenetic modulation: [HDAC] inhibitors] can modulate NF-κB[1] acetylation status
- Microglial phenotype switching: Promoting anti-inflammatory microglial states while preserving protective NF-κB[1] in neurons
NF-κB[1] serves as a signaling hub integrating multiple neurodegeneration-relevant pathways:
- NLRP3 inflammasome: NF-κB[1] provides the priming signal (Signal 1) that upregulates NLRP3 and pro-IL-1β expression; bidirectional amplification loop
- STING pathway]: [cGAS-STING] activates NF-κB[1] in parallel with IRF3, linking DNA damage sensing to inflammation
- JAK-STAT: Cytokine signaling integration; STAT3 cooperates with NF-κB[1] in glial activation
- MAPK pathways: ERK, JNK, and p38 cross-talk with NF-κB[1] at multiple levels
- mTOR: mTORC1 can activate IKK; NF-κB[1] target genes include mTOR regulators
- Nrf2: Counterregulatory relationship — Nrf2 opposes NF-κB[1]-driven oxidative stress; NF-κB[1] can suppress Nrf2 expression
- Tau kinases: NF-κB[1] activates GSK-3β and CDK5, promoting tau hyperphosphorylation]
Recent research has identified NFκB1 (p50/p105) as a potential common biomarker linking Alzheimer's disease and Parkinson's disease disease pathology (Shi et al., 2025):
- NFκB1 expression is altered in both AD and PD brain tissue
- Blood-based NFκB1-related inflammatory signatures correlate with disease progression
- Downstream NF-κB[1] target cytokines (TNF-α, IL-6, IL-1β) in CSF and plasma track with disease severity
- These markers could serve for monitoring therapeutic response to anti-inflammatory interventions
| Method |
Application |
Resolution |
| Immunohistochemistry |
Nuclear p65 localization in tissue sections |
Cellular |
| EMSA (Electrophoretic Mobility Shift Assay) |
DNA-binding activity quantification |
Molecular |
| Western blot |
Protein levels, phosphorylation status |
Molecular |
| NF-κB[1] reporter assays |
Transcriptional activity in live cells |
Cellular |
| ChIP-seq |
Genome-wide NF-κB[1] binding site mapping |
Genomic |
| qPCR of target genes |
Downstream pathway activation |
Molecular |
| Single-cell RNA-seq |
Cell-type-specific NF-κB[1] target expression |
Single-cell |
- iPSC-derived neurons and [microglia: Patient-derived models for studying cell-type-specific NF-κB[1]
- Transgenic AD mice (APP/PS1, 5xFAD): Chronic NF-κB[1] activation recapitulating human AD
- α-synuclein PFF models: [Prion-like] seeding of NF-κB[1]-mediated inflammation
- Conditional NF-κB[1] knockout mice: Cell-type-specific pathway deletion (CamKII-Cre for neurons, CX3CR1-Cre for microglia
- Brain organoids: 3D models for studying glial-neuronal NF-κB[1] cross-talk
The study of Nf Κb (Nuclear Factor Kappa B) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- [Mattson MP, Camandola S. NF-κB[1] in neuronal plasticity and neurodegenerative disorders. J Clin Invest. 2001;107(3):247-254. DOI
- [Hayden MS, Ghosh S. Shared principles in NF-κB[1] signaling. Cell. 2008;132(3):344-362. DOI
- [Karin M, Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-κB[1] activity. Annu Rev Immunol. 2000;18:621-663. DOI
- [Mattson MP. NF-κB[1] in the survival and plasticity of neurons. Mol Neurobiol. 2005;31(1-3]:175-185. DOI
- [Albensi BC, Mattson MP. Evidence for the involvement of TNF and NF-κB[1] in hippocampal synaptic plasticity. Synapse. 2000;35(2):151-159. DOI:10.1002/(SICI
- [Chen CH, et al. NF-κB[1] as a therapeutic target in neurodegenerative diseases. Neurobiol Dis. 2022;165:105642. DOI
- [Ju Hwang C, et al. The pivotal role of NF-kB in the pathogenesis and therapeutics of Alzheimer's Disease. Int J Mol Sci. 2022;23(16):8972. PubMed)
- Jha NK, et al. NF-κB[1] in Alzheimer's Disease: friend or foe? Opposite functions in neurons and glial cells. Mol Neurobiol. 2024. [PubMedhttps://pmc.ncbi.nlm.nih.gov/articles/PMC11545113/
- [Lian H, et al. The impact of astrocytic NF-κB[1] on healthy and Alzheimer's Disease brains. Sci Rep. 2024;14:14876. DOI
- [Snow WM, Albensi BC. Neuronal NF-κB[1] pathways: implications for Alzheimer's Disease. J Alzheimers Dis. 2021;79(3):985-1001. DOI
- Singh SS, et al. NF-κB[1]-mediated neuroinflammation[3] in Parkinson's Disease and potential therapeutic effect of polyphenols. Neurotox Res. 2020;37:491-507. [PubMedhttps://pubmed.ncbi.nlm.nih.gov/31823227/
- [Thakur S, et al. NF-κB[1] pathway and its inhibitors: a promising frontier in the management of Alzheimer's Disease. Biomedicines. 2023;11(9):2587. DOI
- Shi Y, et al. NFκB1: a common biomarker linking Alzheimer's and Parkinson's Disease pathology. Front Neurosci. 2025;19:1589857. [PubMedhttps://pmc.ncbi.nlm.nih.gov/articles/PMC12089106/
- [Bido S, et al. α-Synuclein oligomers potentiate neuroinflammatory NF-κB[1] activity in microglia. Transl Neurodegener. 2024;13:20. DOI
- Gupta SC, et al. NF-κB[1] in Alzheimer's Disease: role in pathogenesis and therapeutic potential. Free Radic Biol Med. 2023;199:56-73.
- [Sun SC. Non-canonical NF-κB[1] signaling pathway. Cell Death Differ. 2011;18(5):719-729. DOI## See Also
-
-
- [Microglia/cell-types/microglia
-
- TREM2 — [Triggering Receptor Expressed on Myeloid Cells 2]
-
- tau protein]## External Links
-
-
-
-